Elsevier

Neurobiology of Aging

Volume 21, Issue 2, March–April 2000, Pages 289-292
Neurobiology of Aging

Neuroimaging
Perfusion abnormalities in prodromal AD

https://doi.org/10.1016/S0197-4580(00)00137-8Get rights and content

Abstract

Cerebral perfusion abnormalities in patients with established Alzheimer’s disease (AD) are most commonly seen in the temporoparietal cortex. As the disease progresses, this perfusion pattern is increasingly prevalent. Recently, investigators have begun to examine the patterns of perfusion among individuals at risk for AD. To date, such studies have been conducted either in individuals who have a progressive memory difficulty but do not yet meet clinical criteria for AD, or in individuals with a genetic risk factor or family history of AD, either with or without a memory problem. These latter studies suggest that a set of brain regions show decreased perfusion during the prodromal phase of AD, and that a brain network or networks with multiple nodes is affected early in the course of AD. These perfusion abnormalities may also shed light on how AD progresses during the prodromal phase of disease and may ultimately lead to improved diagnosis or methods of monitoring response to treatment.

Introduction

Patients with memory complaints are often arrayed along a continuum from normal function through varying degrees of impairment. A crucial question for both patients and clinicians evaluating them is to what extent these complaints are the harbinger of Alzheimer’s disease (AD). This issue is of particular importance as strategies for the prevention or delay of dementia are developed.

However, early detection of AD is complicated by the fact that the disease progresses in an insidious manner, generally starting with mild memory impairments that go unrecognized for years, until a more generalized cognitive decline prompts a diagnosis of dementia. Moreover, mild memory impairments are quite common in the elderly, and not everyone with subtle memory difficulties progresses to develop AD. Current diagnostic techniques have limited utility in predicting which individuals with mild memory impairments will progress over time.

Modern imaging techniques offer one potential method of early detection. In addition, by identifying the neuroimaging measurements useful in the discrimination of prodromal AD, one might learn more about which brain regions are the most affected in the earliest stage of AD.

This review will focus primarily on the area of functional neuroimaging with radiolabeled tracers, specifically Positron Emission Tomography (PET) and Single Photon Emission Tomography (SPECT). There is considerable experience with the application of both techniques to patients with established AD. More recently, these approaches have been expanded to the study of patients who are either in the prodromal phase of AD or to individuals who are at increased risk for developing AD due to family history or genetic profile. Though the findings of these studies are not in uniform agreement, taken together they suggest that a brain network or networks with multiple nodes is affected in the earliest stage of AD, and that functional imaging techniques, such as PET and SPECT, might facilitate early diagnosis. The nature of these findings will be discussed, and their implications for future work will be examined.

Section snippets

Perfusion abnormalities in established AD

Functional imaging techniques, such as PET or SPECT, have demonstrated specific regional abnormalities in brain perfusion in patients with established AD. The most consistent finding to emerge from these studies is that decreased perfusion or metabolism in temporoparietal cortex is common among mildly impaired patients with probable AD (e.g. [7], [8], [9], [10], [17]). Decreased metabolism has been found in other areas as well but is not the predominant pattern reported [23], [25], [32].

Perfusion alterations in prodromal AD

More recently, investigators have demonstrated PET and SPECT alterations in individuals prior to the time that they meet clinical criteria for AD. These studies implicate a set of brain regions that appear to be affected in prodromal AD.

One group of studies has examined individuals at risk for AD because of their genetic profile or family history. One of these studies has been conducted among individuals with a mutation for a dominant gene for AD. However, the majority have been conducted among

Brain networks implicated in prodromal AD

Perfusion alterations in the hippocampal complex in prodromal AD are consistent with a large body of knowledge indicating that this region is involved at the earliest stage of this disorder (e.g. [3], [11], [15]). Recent neuropathological studies indicate that the pathological hallmarks of AD (i.e. the neurofibrillary tangles and neuritic plaques) are first evident in the entorhinal cortex [11]. This finding is consistent with the fact that most patients with AD have a progressive memory

Future directions in the study of perfusion alterations in prodromal AD

Taken together, these data suggest that there are alterations in a distributed brain network or networks in prodromal AD, which are measurable with functional neuroimaging. It is not yet clear whether these measures of perfusion or metabolism can be used to identify individuals in the prodromal phase of AD for clinical intervention, because the accuracy with which such individuals can be identified with certainty is still limited. In addition, it is not yet known whether the findings described

Conclusion

Considerable research efforts have been focused on the development of an accurate, noninvasive laboratory test for the presence of AD pathology, which can be easily and widely applied. The potential for effective treatments for AD has further motivated a vigorous research effort to identify surrogate markers of early AD pathology. Neuroimaging methods have the potential to satisfy these requirements because they are acquired noninvasively, using techniques and equipment that are widely

References (43)

  • T. Farkas et al.

    18F-2-deoxy-2-fluoro-d-glucose as a tracer in the positron emission tomographic study of senile dementia

    Am J Psychiatry

    (1982)
  • N.L. Foster et al.

    Cortical abnormalities in Alzheimer’s disease

    Ann Neurol

    (1984)
  • R.P. Friedland et al.

    Regional cerebral metabolic alterations in dementia of the Alzheimer typepositron emission tomography with [18F]fluorodeoxyglucose

    J Comput Assist Tomogr

    (1983)
  • T. Gómez–Isla et al.

    Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer’s disease

    J Neurosci

    (1996)
  • T. Gómez–Isla et al.

    Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer’s disease

    Ann Neurol

    (1997)
  • M. Higuchi et al.

    Regional cerebral glucose utilization is modulated by the dosage of apolipoprotein E type 4 allele and alpha1-antichymotrypsin type A allele in Alzheimer’s disease

    Neuroreport

    (1997)
  • B.L. Holman et al.

    The scintigraphic appearance of Alzheimer’s diseasea prospective study using technetium-99m-HMPAO SPECT

    J Nucl Med

    (1992)
  • B.T. Hyman et al.

    Alzheimer’s diseasecell-specific pathology isolates the hippocampal formation

    Science

    (1984)
  • K. Jobst et al.

    Accurate prediction of histologically confirmed Alzheimer’s disease and the differential diagnosis of dementiathe use of NINCDS-ADRDA and DSM III-R criteria, SPECT, X-ray CT and APOE4 medial temporal lobe dementias

    Int Psychogeriatr

    (1997)
  • K.A. Johnson et al.

    Quantitative brain SPECT in Alzheimer’s disease and normal aging

    J Nucl Med

    (1993)
  • Johnson KA, Lopera F, Jones K, et al. Presenilin-1-associated abnormalities in regional cerebral perfusion. Society for...
  • Cited by (97)

    • Differential blockade by huperzine A and donepezil of sympathetic nicotinic acetylcholine receptor-mediated nitrergic neurogenic dilations in porcine basilar arteries

      2020, European Journal of Pharmacology
      Citation Excerpt :

      Norepinephrine subsequently induces NO production in the neighboring cholinergic-nitrergic nerves via activating β2-adrenergic receptors, leading to nitrergic dilations of cerebral arteries (Chen and Lee, 1993; Lee et al., 2000). The nicotinic acetylcholine receptor-blocking agents may alter the neurogenic control of cerebral arteries causing a reduction in blood flow in the brainstem (Faraci et al., 1987; Faraci and Heistad, 1990), which may further decrease the regional cerebral blood supply in patients with Alzheimer's disease (Hirsch et al., 1997; Johnson and Albert, 2000). Huperzine A, extracted from Huperzia serrata (Tang et al., 1994), is a potent and selective acetylcholinesterase inhibitor and widely used in China for Alzheimer's disease treatment (Jiang et al., 2000; Zhang, 2012).

    • The correlation between cerebral arterial pulsatility and cognitive dysfunction in Alzheimer's disease patients

      2017, Journal of the Neurological Sciences
      Citation Excerpt :

      Chronic cerebral hypoperfusion also down-regulates low density lipoprotein receptor-related protein 1 (LRP1), which may interfere the clearance of Aβ and overproduction of Aβ [2]. These hypotheses are regarded as possible pathophysiological explanations for the link between vascular factors and neurodegenerative dementia in many epidemiological and experimental studies [3–6]. Transcranial Doppler sonography (TCD) is a non-invasive method to measure the blood flow velocity, which may represent the cerebral perfusion status.

    • Stroke, Cognitive Function, and Alzheimer's Disease

      2016, Genes, Environment and Alzheimer's Disease
    View all citing articles on Scopus
    View full text